These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 21480817)

  • 1. Pharmacogenetics of tacrolimus after renal transplantation: analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes.
    Tavira B; Coto E; Díaz-Corte C; Ortega F; Arias M; Torres A; Díaz JM; Selgas R; López-Larrea C; Campistol JM; Alvarez V;
    Clin Chem Lab Med; 2011 May; 49(5):825-33. PubMed ID: 21480817
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase.
    Aouam K; Kolsi A; Kerkeni E; Ben Fredj N; Chaabane A; Monastiri K; Boughattas N
    Pharmacogenomics; 2015 Dec; 16(18):2045-54. PubMed ID: 26615671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CYP3A5*3 and ABCB1 61A>G Significantly Influence Dose-adjusted Trough Blood Tacrolimus Concentrations in the First Three Months Post-Kidney Transplantation.
    Hu R; Barratt DT; Coller JK; Sallustio BC; Somogyi AA
    Basic Clin Pharmacol Toxicol; 2018 Sep; 123(3):320-326. PubMed ID: 29603629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of CYP3A4-392A/G, CYP3A5-6986A/G, and ABCB1-3435C/T Polymorphisms with Tacrolimus Dose, Serum Concentration, and Biochemical Parameters in Mexican Patients with Kidney Transplant.
    Alatorre-Moreno EV; Saldaña-Cruz AM; Pérez-Guerrero EE; Morán-Moguel MC; Contreras-Haro B; López-de La Mora DA; Dávalos-Rodríguez IP; Marín-Medina A; Rivera-Cameras A; Balderas-Peña LA; Gómez-Ramos JJ; Cortés-Sanabria L; Salazar-Páramo M
    Genes (Basel); 2024 Apr; 15(4):. PubMed ID: 38674430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CYP3A5 and CYP3A4, but not ABCB1 polymorphisms affect tacrolimus dose-adjusted trough concentrations in kidney transplant recipients.
    Kurzawski M; Dąbrowska J; Dziewanowski K; Domański L; Perużyńska M; Droździk M
    Pharmacogenomics; 2014 Feb; 15(2):179-88. PubMed ID: 24444408
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of CYP3A5 polymorphisms on the pharmacokinetics of tacrolimus in adolescent kidney transplant recipients.
    Tirelli S; Ferraresso M; Ghio L; Meregalli E; Martina V; Belingheri M; Mattiello C; Torresani E; Edefonti A
    Med Sci Monit; 2008 May; 14(5):CR251-254. PubMed ID: 18443548
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polymorphism of the CYP3A5 gene and its effect on tacrolimus blood level.
    Nair SS; Sarasamma S; Gracious N; George J; Anish TS; Radhakrishnan R
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():197-200. PubMed ID: 25894154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation.
    Lloberas N; Elens L; Llaudó I; Padullés A; van Gelder T; Hesselink DA; Colom H; Andreu F; Torras J; Bestard O; Cruzado JM; Gil-Vernet S; van Schaik R; Grinyó JM
    Pharmacogenet Genomics; 2017 Sep; 27(9):313-322. PubMed ID: 28704257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.
    Tang JT; Andrews LM; van Gelder T; Shi YY; van Schaik RH; Wang LL; Hesselink DA
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):555-65. PubMed ID: 27010623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant impact of gene polymorphisms on tacrolimus but not cyclosporine dosing in Asian renal transplant recipients.
    Loh PT; Lou HX; Zhao Y; Chin YM; Vathsala A
    Transplant Proc; 2008 Jun; 40(5):1690-5. PubMed ID: 18589174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of CYP3A4*22 allele on tacrolimus pharmacokinetics in early period after renal transplantation: toward updated genotype-based dosage guidelines.
    Elens L; Capron A; van Schaik RH; De Meyer M; De Pauw L; Eddour DC; Latinne D; Wallemacq P; Mourad M; Haufroid V
    Ther Drug Monit; 2013 Oct; 35(5):608-16. PubMed ID: 24052064
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and CYP3A5 pharmacogenetic differences between once- and twice-daily tacrolimus from the first dosing day to 1 year after renal transplantation.
    Satoh S; Niioka T; Kagaya H; Numakura K; Inoue T; Saito M; Komine N; Narita S; Tsuchiya N; Habuchi T; Miura M
    Pharmacogenomics; 2014 Aug; 15(11):1495-506. PubMed ID: 25303300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.
    Santoro A; Felipe CR; Tedesco-Silva H; Medina-Pestana JO; Struchiner CJ; Ojopi EB; Suarez-Kurtz G
    Pharmacogenomics; 2011 Sep; 12(9):1293-303. PubMed ID: 21806386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
    Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
    Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of pharmacokinetics and pharmacogenetics of once- and twice-daily tacrolimus in the early stage after renal transplantation.
    Niioka T; Satoh S; Kagaya H; Numakura K; Inoue T; Saito M; Narita S; Tsuchiya N; Habuchi T; Miura M
    Transplantation; 2012 Nov; 94(10):1013-9. PubMed ID: 23073468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of CYP3A5 and MDR1 polymorphisms on tacrolimus dosage requirements and trough concentrations in pediatric renal transplant recipients.
    Shilbayeh S; Zmeili R; Almardini RI
    Saudi J Kidney Dis Transpl; 2013 Nov; 24(6):1125-36. PubMed ID: 24231473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tools for a personalized tacrolimus dose adjustment in the follow-up of renal transplant recipients. Metabolizing phenotype according to CYP3A genetic polymorphisms versus concentration-dose ratio.
    Vidal-Alabró A; Colom H; Fontova P; Cerezo G; Melilli E; Montero N; Coloma A; Manonelles A; Favà A; Cruzado JM; Torras J; Grinyó JM; Lloberas N
    Nefrologia (Engl Ed); 2024; 44(2):204-216. PubMed ID: 38614890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients.
    Quteineh L; Verstuyft C; Furlan V; Durrbach A; Letierce A; Ferlicot S; Taburet AM; Charpentier B; Becquemont L
    Basic Clin Pharmacol Toxicol; 2008 Dec; 103(6):546-52. PubMed ID: 19067682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics of calcineurin inhibitors in renal transplantation.
    Coto E; Tavira B
    Transplantation; 2009 Aug; 88(3 Suppl):S62-7. PubMed ID: 19667964
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of CYP3A4 and CYP3A5 polymorphisms on tacrolimus and sirolimus exposure in stable kidney transplant recipients.
    Tamashiro EY; Felipe CR; Genvigir FDV; Rodrigues AC; Campos AB; Hirata RDC; Tedesco-Silva H; Medina-Pestana JO
    Drug Metab Pers Ther; 2017 May; 32(2):89-95. PubMed ID: 28593920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.